Cargando…
A review on Promising vaccine development progress for COVID-19 disease
The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) that causes corona virus disease 2019 (COVID-19) and its impact on in the world have made imperative progress to develop an effective and safe vaccine. Despite several measures undertaken, the spr...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier España, S.L.U.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695440/ http://dx.doi.org/10.1016/j.vacune.2020.10.009 |
_version_ | 1783615189538570240 |
---|---|
author | Belete, Tafere Mulaw |
author_facet | Belete, Tafere Mulaw |
author_sort | Belete, Tafere Mulaw |
collection | PubMed |
description | The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) that causes corona virus disease 2019 (COVID-19) and its impact on in the world have made imperative progress to develop an effective and safe vaccine. Despite several measures undertaken, the spread of this virus is ongoing. So far, more than 1,560,000 cases and 1000,000 deaths occurred in the world. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS. However, currently, no approved vaccine exists for these coronavirus strains. Such Previous research efforts to develop a coronavirus vaccine in the years following the 2003 pandemic have opened the door for the scientist to design a new vaccine for the COVID-19. Both SARS-CoV and SARS-CoV-2 has a high degree of genetic similarity and bind to the same host cell ACE2 receptor. By using different vaccine development platforms including whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines several candidates displayed efficacy in vitro studies but few progressed to clinical trials. This review provides a brief introduction of the general features of SARS-CoV-2 and discusses the current progress of ongoing advances in designing vaccine development efforts to counter COVID-19. |
format | Online Article Text |
id | pubmed-7695440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76954402020-12-01 A review on Promising vaccine development progress for COVID-19 disease Belete, Tafere Mulaw Vacunas (English Edition) Revisión The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) that causes corona virus disease 2019 (COVID-19) and its impact on in the world have made imperative progress to develop an effective and safe vaccine. Despite several measures undertaken, the spread of this virus is ongoing. So far, more than 1,560,000 cases and 1000,000 deaths occurred in the world. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS. However, currently, no approved vaccine exists for these coronavirus strains. Such Previous research efforts to develop a coronavirus vaccine in the years following the 2003 pandemic have opened the door for the scientist to design a new vaccine for the COVID-19. Both SARS-CoV and SARS-CoV-2 has a high degree of genetic similarity and bind to the same host cell ACE2 receptor. By using different vaccine development platforms including whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines several candidates displayed efficacy in vitro studies but few progressed to clinical trials. This review provides a brief introduction of the general features of SARS-CoV-2 and discusses the current progress of ongoing advances in designing vaccine development efforts to counter COVID-19. Published by Elsevier España, S.L.U. 2020 2020-11-27 /pmc/articles/PMC7695440/ http://dx.doi.org/10.1016/j.vacune.2020.10.009 Text en © 2020 Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Revisión Belete, Tafere Mulaw A review on Promising vaccine development progress for COVID-19 disease |
title | A review on Promising vaccine development progress for COVID-19 disease |
title_full | A review on Promising vaccine development progress for COVID-19 disease |
title_fullStr | A review on Promising vaccine development progress for COVID-19 disease |
title_full_unstemmed | A review on Promising vaccine development progress for COVID-19 disease |
title_short | A review on Promising vaccine development progress for COVID-19 disease |
title_sort | review on promising vaccine development progress for covid-19 disease |
topic | Revisión |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695440/ http://dx.doi.org/10.1016/j.vacune.2020.10.009 |
work_keys_str_mv | AT beletetaferemulaw areviewonpromisingvaccinedevelopmentprogressforcovid19disease AT beletetaferemulaw reviewonpromisingvaccinedevelopmentprogressforcovid19disease |